SpringerLink
Log in

Relationship between histopathological therapeutic effect and prognosis in oral cancer patients after preoperative S-1 chemotherapy followed by surgery

  • Research
  • Published:
Clinical Oral Investigations Aims and scope Submit manuscript

Abstract

Objectives

Preoperative S-1 chemotherapy is administered to prevent tumor proliferation before surgery in oral squamous cell carcinoma (OSCC). The aim of this study was to investigate the relationship between the histological therapeutic effect and prognosis in patients with OSCC after pre-operative S-1 chemotherapy.

Materials and methods

Among 461 OSCC cases, 281 patients who received preoperative S-1 chemotherapy were compared with 180 patients that did not receive chemotherapy to determine the histological therapeutic effect in the resected specimens and the differences in relapse-free survival.

Results

The histological chemotherapeutic effect was well correlated with the subsequent prognosis. In an examination of the combined effect of treatment and ypStage, the groups with good S-1 treatment effects had extremely good prognoses, even if the postoperative resection specimens were within the same ypStage. In a stratified search of patients who received S-1 for more than 7 days and who had a significantly better prognosis than those who did not receive S-1, it was found that the prognosis was significantly better for patients with tongue cancer according to site; furthermore, tongue cancer, age under 70 years of age, male sex, and clinical stage I were factors associated with a significantly better prognosis.

Conclusions

Even if the postoperative resection specimens were within the same ypStage, the groups that responded to S-1 treatment were considered to have extremely good prognoses.

Clinical relevance

A good adaptation for S-1 was tongue cancer, and especially tongue cancer with cStage I, male sex, and age less than 70 years old.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

The data are not publicly available due to privacy or ethical restrictions.

Abbreviations

OSCC:

Oral squamous cell carcinoma

References

  1. Shirasaka T, Shimamoto Y, Ohshima H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557

    Article  PubMed  Google Scholar 

  2. Schoffski P (2004) The modulated oral fluropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15:85–106

    Article  PubMed  Google Scholar 

  3. Seki-Soda M, Sano T, Ogawa M, Yokoo S, Oyama T (2021) CD15+ tumor infiltrating granulocytic cells can predict recurrence and their depletion is accompanied by good responses to S-1 with oral cancer. Head Neck 43:2457–2467

    Article  PubMed  Google Scholar 

  4. Tsukuda M, Kida A, Fujii M et al (2005) Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer 93:884–889

    Article  PubMed Central  Google Scholar 

  5. Satoh T, Sakata Y (2012) S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother 13:1943–1959

    Article  PubMed  Google Scholar 

  6. Imano N, Murakami Y, Kubo K, Kawahara D, Takeuchi Y, Nishibuchi I, Kimura T, Kochi M, Takakura Y, Shimizu W, Egi H, Uegami S, Ohge H, Takahashi S, Ohdan H, Nagata Y (2021) Efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for locally advanced rectal cancer. J Radiat Res 62:300–308

    Article  PubMed  Google Scholar 

  7. Sawasaki M, Tsubamoto H, Nakamoto Y, Kakuno A, Sonoda T (2020) S-1, oxaliplatin, Nab-paclitaxel and itraconazole for conversion surgery for advanced or recurrent gastric cancer. Anticancer Res 40:991–997

    Article  PubMed  Google Scholar 

  8. Kosaka T, Akiyama H, Miyamoto H, Sato S, Tanaka Y, Sato K, Kunisaki C, Endo I (2019) Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer. Cancer Chemother Pharmacol 83:1047–1055

    Article  PubMed  Google Scholar 

  9. Nakamoto Y, Noda M, Mikami R, Tokunaga Y, Okumoto T, Kawamura T, Fujiwara H, Doi S, Tomita N (2020) Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. Int J Clin Oncol 25:1285–1290

    Article  PubMed  Google Scholar 

  10. Gao SG, Jia RN, Feng XS, **e XH, Shan TY, Pan LX, Song NS, Wang YF, Ding KL, Wang LD (2011) Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma. World J Gastroenterol 17:5221–5226

    Article  PubMed  PubMed Central  Google Scholar 

  11. Nomura T, Murakami R, Toya R et al (2010) Phase II study of preoperative concurrent chemoradiation therapy with S-1 in patients with T4 oral squamous cell carcinoma. Int J Radiat Oncol Biol Phys 76:1347–1352

    Article  PubMed  Google Scholar 

  12. Harada H, Omura K, Tomioka H et al (2013) Multicenter phase II trial of preoperative chemoradiotherapy with S-1 for locally advanced oral squamous cell carcinoma. Cancer Chemother Pharmacol 71:1059–1064

    Article  PubMed  PubMed Central  Google Scholar 

  13. Marta GN, Riera R, Bossi P, Zhong LP, Licitra L, Macedo CR, de Castro JG, Carvalho AL, William WN Jr, Kowalski LP (2015) Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: systematic review and meta-analysis. Eur J Cancer 51:2596–2603

    Article  PubMed  Google Scholar 

  14. Matsumiya Y, Imai T, Takeshita A, Meshii N, Katou I, Iwai S, Suematsu M, Omae M, Kanesaki T, Ota Y, Onishi T, Amino K, Sumi T, Niki A, Ueda M, Nakazawa M (2019) Clinicopathological evaluation of preoperative chemotherapy containing S-1 as a treatment for patients with oral squamous cell carcinoma during waiting time for surgery. Gan To Kagaku Ryoho 46:1027–1031

    PubMed  Google Scholar 

  15. Namikawa T, Ishida N, Tsuda S, Fujisawa K, Munekage E, Iwabu J, Munekage M, Uemura S, Tsujii S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki KI (2018) Pathological complete response by S-1 chemotherapy in advanced gastric cancer. In Vivo 32:1211–1216

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M (2013) Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31:1640–1648

    Article  PubMed  Google Scholar 

  17. Seki M, Sano T, Ogawa M, Yokoo S, Oyama T (2019) Histopathological changes in tumor budding between biopsy and resected specimens from patients treated with preoperative S-1 chemotherapy for oral cancer. J Oral Pathol Med 48:880–887

    Article  Google Scholar 

  18. Buzdar AU (2007) Preoperative chemotherapy treatment of breast cancer–a review. Cancer 110:2394–2407

    Article  Google Scholar 

  19. Vega EA, Kutlu OC, Salehi O, James D, Alarcon SV, Herrick B, Krishnan S, Kozyreva O, Conrad C (2020) Preoperative chemotherapy for pancreatic cancer improves survival and R0 rate even in early stage I. J Gastrointest Surg 24:2409–2415

    Article  PubMed  Google Scholar 

  20. Arredondo J, Pastor E, Simó V, Beltrán M, Castañón C, Magdaleno MC, Matanza I, Notarnicola M, Ielpo B (2020) Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review. Tech Coloproctol 24:1001–1015

    Article  PubMed  Google Scholar 

  21. Hanna GG, Siva S, Plumridge N, Solomon B, Ball DL (2014) Preoperative chemotherapy for non-small-cell lung cancer. Lancet 384:232–233

    Article  Google Scholar 

  22. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. MAGIC trial participants. N Engl J Med 355:11–20

    Article  PubMed  Google Scholar 

  23. Izumo T, Kirita T, Ariji E, Ozeki S, Okada N, Okabe S et al (2012) General rules for clinical and pathological studies on oral cancer: a synopsis. Jpn J Clin Oncol 42:1099–1109

    Article  PubMed  Google Scholar 

  24. Tsukahara K, Kubota A, Hasegawa Y, Takemura H, Terada T, Taguchi T et al (2015) Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC). PLoS One 10:e0116965

    Article  PubMed  PubMed Central  Google Scholar 

  25. Hirakawa H, Hanai N, Suzuki H, Nishikawa D, Matayoshi S, Hasegawa Y, Suzuki M (2017) Prognostic importance of pathological response to neoadjuvant chemotherapy followed by definitive surgery in advanced oral squamous cell carcinoma. Jpn J Clin Oncol 47:1038–1046

    Article  PubMed  Google Scholar 

  26. Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, Hubert A, Baniyash M (2014) Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res 74:6022–6035

    Article  PubMed  Google Scholar 

  27. Matsuda Y, Ohkubo S, Nakano-Narusawa Y, Fukumura Y, Hirabayashi K, Yamaguchi H, Sahara Y, Kawanishi A, Takahashi S, Arai T, Kojima M, Mino-Kenudson M (2020) Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Sci Rep 10:18278

    Article  PubMed  PubMed Central  Google Scholar 

  28. Tanaka Y (2008) The state and ploblems of judging histopathological effect. J Jpn Soc Oral Tumor 20:255–261

    Article  Google Scholar 

  29. Choi N, Noh Y, Lee EK, Chung M, Baek CH, Baek KH, Jeong HS (2017) Discrepancy between cTNM and pTNM staging of oral cavity cancers and its prognostic significance. J Surg Oncol 115:1011–1018

    Article  Google Scholar 

  30. Almahmoudi R, Kasanen M, Sieviläinen M, Salem A, Pirinen M, Salo T, Al-Samadi A (2019) Prognostic value of blood and lymphatic vessel markers in tongue cancer: a systematic review. Cancer Sci 110:3424–3433

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8511, Japan

    Mai Seki, Takaaki Sano & Tetsunari Oyama

  2. Department of Oral and Maxillofacial Surgery, and Plastic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan

    Mai Seki, Masaru Ogawa, Yu Takayama & Satoshi Yokoo

Authors
  1. Mai Seki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takaaki Sano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaru Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Takayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoshi Yokoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tetsunari Oyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MSS and TS reviewed the slides and wrote the paper. MO, YT, and SY provided the clinical information. TO provided expert pathological advice. All authors contributed to the discussion and final approval of the manuscript.

Corresponding author

Correspondence to Mai Seki.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval

The study was approved by the Institutional Review Board for Clinical Research of Gunma University Hospital and conforms to the Declaration of Helsinki.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seki, M., Sano, T., Ogawa, M. et al. Relationship between histopathological therapeutic effect and prognosis in oral cancer patients after preoperative S-1 chemotherapy followed by surgery. Clin Oral Invest 27, 4817–4826 (2023). https://doi.org/10.1007/s00784-023-05112-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00784-023-05112-0

Keywords

Search

Navigation